Literature DB >> 21448093

Quality of life in patients with bipolar disorder--a comparison with schizophrenic patients and healthy controls.

Klara Latalova1, Jan Prasko, Tomas Diveky, Dana Kamaradova, Hana Velartova.   

Abstract

BACKGROUND: In the past, the first goal of bipolar disorder treatment was the reduction of symptoms of mania or depression, rather than the recovery of social functioning. Recently, as a result of an increased emphasis on patient needs, the concept of quality of life (QoL) has been brought into the treatment of physical illnesses. SUBJECTS AND METHODS: The purpose of the present study was to examine QoL data in patients with bipolar disorder in clinical remission and to determine the extent of the effects of demographic and clinical data on QoL in these patients. The second aim was to compare the QoL data of these patients to that of patients with schizophrenia in clinical remission and to that of healthy controls. Data were obtained using a QoL questionnaire (Quality of Life Enjoyment and Satisfaction Questionnaire, or Q-LES-Q) for 41 bipolar patients in clinical remission. The data were then compared with the data of 40 schizophrenic patients in clinical remission and with 40 healthy controls.
RESULTS: There were higher mean scores in most Q-LES-Q summary scales in the bipolar patients than in the schizophrenic patients. There were higher mean scores in the bipolar patients in some summary scales than in the healthy controls.
CONCLUSIONS: Our results suggest the same or higher subjective QoL in bipolar patients in clinical remission in comparison with healthy controls and higher subjective QoL in bipolar patients in clinical remission than in schizophrenic patients in clinical remission.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21448093

Source DB:  PubMed          Journal:  Psychiatr Danub        ISSN: 0353-5053            Impact factor:   1.063


  7 in total

1.  Correlates of real world executive dysfunction in bipolar I disorder.

Authors:  Amy T Peters; Andrew D Peckham; Jonathan P Stange; Louisa G Sylvia; Natasha S Hansen; Stephanie Salcedo; Scott L Rauch; Andrew A Nierenberg; Darin D Dougherty; Thilo Deckersbach
Journal:  J Psychiatr Res       Date:  2014-03-02       Impact factor: 4.791

2.  Are self-stigma, quality of life, and clinical data interrelated in schizophrenia spectrum patients? A cross-sectional outpatient study.

Authors:  Michaela Holubova; Jan Prasko; Klara Latalova; Marie Ociskova; Aleš Grambal; Dana Kamaradova; Kristyna Vrbova; Radovan Hruby
Journal:  Patient Prefer Adherence       Date:  2016-03-04       Impact factor: 2.711

3.  Quality of life in borderline patients comorbid with anxiety spectrum disorders - a cross-sectional study.

Authors:  Ales Grambal; Jan Prasko; Dana Kamaradova; Klara Latalova; Michaela Holubova; Zuzana Sedláčková; Radovan Hruby
Journal:  Patient Prefer Adherence       Date:  2016-08-01       Impact factor: 2.711

4.  Comparison of self-stigma and quality of life in patients with depressive disorders and schizophrenia spectrum disorders - a cross-sectional study.

Authors:  Michaela Holubova; Jan Prasko; Stanislav Matousek; Klara Latalova; Marketa Marackova; Kristyna Vrbova; Aleš Grambal; Milos Slepecky; Marta Zatkova
Journal:  Neuropsychiatr Dis Treat       Date:  2016-11-24       Impact factor: 2.570

5.  Quality of life, self-stigma, and hope in schizophrenia spectrum disorders: a cross-sectional study.

Authors:  Kristyna Vrbova; Jan Prasko; Marie Ociskova; Dana Kamaradova; Marketa Marackova; Michaela Holubova; Ales Grambal; Milos Slepecky; Klara Latalova
Journal:  Neuropsychiatr Dis Treat       Date:  2017-02-23       Impact factor: 2.570

6.  Double blind randomized controlled trial of deep brain stimulation for obsessive-compulsive disorder: Clinical trial design.

Authors:  Nicole C R McLaughlin; Darin D Dougherty; Emad Eskandar; Herbert Ward; Kelly D Foote; Donald A Malone; Andre Machado; William Wong; Mark Sedrak; Wayne Goodman; Brian H Kopell; Fuad Issa; Donald C Shields; Osama A Abulseoud; Kendall Lee; Mark A Frye; Alik S Widge; Thilo Deckersbach; Michael S Okun; Dawn Bowers; Russell M Bauer; Dana Mason; Cynthia S Kubu; Ivan Bernstein; Kyle Lapidus; David L Rosenthal; Robert L Jenkins; Cynthia Read; Paul F Malloy; Stephen Salloway; David R Strong; Richard N Jones; Steven A Rasmussen; Benjamin D Greenberg
Journal:  Contemp Clin Trials Commun       Date:  2021-06-05

7.  Effectiveness of integrated care including therapeutic assertive community treatment in severe schizophrenia-spectrum and bipolar I disorders: Four-year follow-up of the ACCESS II study.

Authors:  Daniel Schöttle; Benno G Schimmelmann; Friederike Ruppelt; Alexandra Bussopulos; Marietta Frieling; Evangelia Nika; Luise Antonia Nawara; Dietmar Golks; Andrea Kerstan; Matthias Lange; Michael Schödlbauer; Anne Daubmann; Karl Wegscheider; Anja Rohenkohl; Gizem Sarikaya; Mary Sengutta; Daniel Luedecke; Linus Wittmann; Gunda Ohm; Christina Meigel-Schleiff; Jürgen Gallinat; Klaus Wiedemann; Thomas Bock; Anne Karow; Martin Lambert
Journal:  PLoS One       Date:  2018-02-27       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.